Cardiac care in China — in context
How strong is cardiovascular care in China?
If you are researching cardiology in China or heart treatment in China for yourself or a family member, the practical question is simple: how does care here compare with the best centres abroad? Below is a grounded, numbers-based comparison written for international patients.
China’s leading cardiovascular institutions — Fuwai Hospital (the National Center for Cardiovascular Diseases), Zhongshan Hospital of Fudan University and Beijing Anzhen Hospital — sit in the country’s first tier. Other centres such as Shanghai Chest, Ruijin and West China are strong in sub-specialties like coronary disease, arrhythmia and structural heart disease. As an international benchmark, the Cleveland Clinic’s Heart, Vascular & Thoracic Institute (ranked #1 in U.S. News Cardiology & Heart Surgery for roughly 30 consecutive years) and Mayo Clinic (Newsweek’s #1 hospital in the world, 2025) remain the global reference points for the field.
Equipment and technology
Top tier-3 hospitals are routinely equipped with high-end cath labs (DSA), IVUS/OCT intravascular imaging, ECMO, hybrid operating rooms, 3.0T MRI and dual-source CT — largely on par with international standards. Adoption of interventional platforms is fast: TAVR centres grew from fewer than 10 in 2017 to more than 600 by 2024.
Treatment scale and outcomes
In 2024, China performed about 2.24 million PCI (coronary stent) procedures across 3,785+ hospitals, up ~16% year on year. National in-hospital PCI mortality was 0.6%. At Fuwai, 6,479 valve surgeries in 2023 carried a 30-day mortality of just 0.5%. For complex arrhythmia ablation and aortic hybrid surgery, leading Chinese centres are firmly first-tier.
Medications and affordability
Standard evidence-based therapies — statins, ACE inhibitors/ARBs, antiplatelets, DOACs, SGLT2 inhibitors — are widely available, and because of domestic generics and biosimilars, heart surgery cost in China and everyday cardiac medication prices are substantially lower than in the US or Europe. Approval of novel drugs has accelerated, though the very newest agents can still reach China months to years after the US/EU; verify availability per drug.
Talent and research
China has a large specialist workforce, with many clinicians trained internationally, and rapidly growing research output in Circulation, European Heart Journal and peer journals. International leaders still set more original research and clinical guidelines, but the gap is narrowing.
Cardiovascular care in China vs the global benchmark — key figures (2023–2024)
| Metric | China | Global benchmark (Cleveland / Mayo) | Read |
| PCI volume (2024) | ~2.24 million procedures / 3,785+ hospitals | US single-centre volume in the tens of thousands | Among the largest nationally |
| TAVR volume (2024) | >15,000 / 600+ centres | More mature US market, larger volume | China growing faster |
| In-hospital PCI mortality (2024) | 0.6% | Advanced centres <1% | Same tier |
| Fuwai valve surgery 30-day mortality (2023) | 0.5% (6,479 cases) | Top international centres comparable | World-class |
| Specialty reputation | Fuwai double #1 in Fudan | Cleveland #1 cardiology ~30 yrs; Mayo #1 global 2025 | Reputation comparable |
The figures show China is already at or near world-class on scale and key outcomes. The real gaps remain in original research, access to the very newest drugs and devices, and overall system maturity — each addressed above.
Beyond the four dimensions
Common questions from international patients
Can foreigners get heart surgery in China?
Yes. Major cardiovascular centres regularly treat international patients, and many have dedicated international departments. Suitability is decided case by case by the hospital’s licensed clinicians.
Can Americans get cardiac treatment in China?
Yes. American patients commonly travel to China for planned cardiac evaluation, intervention or surgery, often because of lower cost and shorter waits. Bring your records and allow time for translation and coordination.
Do Chinese hospitals speak English?
The largest tertiary centres and their international departments provide English-speaking doctors and coordinators. For other settings, a medical interpreter or coordinator (such as Wellward China) is recommended.
How to see a cardiologist in China as a foreigner?
Through a hospital international clinic, a local coordinator, or by contacting a service like Wellward China with your records and goals. Appointments at top centres can often be arranged faster than in many public systems.
Heart surgery cost in China vs the US?
Comparable procedures are typically a fraction of US prices in China, largely because of lower hospital and staffing costs and widely available generics. Exact figures vary by hospital, procedure and whether implants are used — request a written quote per case.
Why is heart surgery so expensive in the US?
US prices reflect hospital charges, specialist fees, insurance administration and high implant costs. That gap is exactly why some international patients explore heart surgery cost in China vs USA as a pragmatic alternative.
Practical takeaway for international patients
For common, high-prevalence cardiac conditions — standardised diagnosis, intervention or surgery — China’s top centres are highly competitive on quality, access and cost. For extremely rare or cutting-edge experimental therapies, China can be an efficient, pragmatic option, ideally combined with an international second opinion.
For reference, not medical advice. This page is general information and does not replace an in-person evaluation by a licensed clinician. Figures are from the public sources listed and change over time; the “US single-centre volume” figure is an order-of-magnitude description, not a precise statistic. Hospital rankings, procedures, costs and waiting times should be confirmed with each hospital’s official, current information. A qualified reviewer should check this content before publication, and an “updated” date should be shown.
Sources. (1) Fudan Hospital Specialty Reputation Rankings 2024 (Cardiovascular Medicine & Cardiac Surgery: Fuwai #1). (2) China Cardiovascular Quality Report 2024 (PCI 2.243M, 3,796 hospitals, 0.6% mortality, intravascular imaging 22%). (3) Fuwai Hospital Cardiovascular Surgery Annual Report 2023 (6,479 valve surgeries, 0.5% 30-day mortality). (4) TAVR Clinical Pathway 2024 (Chinese Journal of Cardiology: 600+ centres, >15,000/yr). (5) U.S. News Best Hospitals (Cleveland Clinic #1 Cardiology ~30 yrs); Newsweek World’s Best Hospitals 2025 (Mayo Clinic #1).